IFNG and neoplasm: Of these, Clostridium novyi-NT AC and Clostridium sporogenes NCIMB 10696 are modified to produce anti-HIF1A antibodies, inhibiting the angiogenic signaling pathway at an early stage (34), and Clostridium sporogenes ATCC 3584 is modified to deliver IL12, selectively amplifying IFN gamma secretion and affecting tumor growth (35).